Athira Pharma changed its name last year to reflect its focus on regenerative medicine. Now, it’s snagged $85 million to advance those medicines, which includes bankrolling a phase 2/3 trial in Alzheimer’s for its lead asset. Formerly known as M3 Biotechnology, the Seattle-based biotech landed on its new moniker, derived from the Arabic word meaning […]

The foundation of Athira Pharma began while Leen Kawas was earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago. Fast forward to today and the Seattle biotech startup is inching closer to FDA approval for its drug therapy that can restore brain function and help people suffering from brain diseases such as Alzheimer’s and […]

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Dr RJ Tesi, CEO of INmune Bio about its clinical program that seeks to determine whether its existing TNF inhibitors can be repurposed to prevents complications of cytokine storm caused by COVID-19. Dr Tesi gives solemn insight […]